Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10038046 | 0.85 | POLB (0.79) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL28354072 | 0.85 | POLB (0.79) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL521639 | 0.85 | POLB (0.79) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL19546873 | 0.85 | POLB (0.79) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL10014710 | 0.83 | USP2 (0.76) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL5512058 | 0.83 | POLB (0.65) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL4547084 | 0.82 | MEN1 (0.63) | POLBALDH1A1HPGDKDM4EHSP90AA1 | |
| SCHEMBL17369114 | 0.81 | SMN1; SMN2 (0.63) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL12549613 | 0.81 | SMN1; SMN2 (0.63) | POLBALDH1A1HPGDUSP2KDM4E | |
| SCHEMBL12549856 | 0.81 | SMN1; SMN2 (0.63) | POLBALDH1A1HPGDUSP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450348-B1 | NOVEL DIARYLAMINE COMPOUND, AND ANTI-AGING AGENT, POLYMER COMPOSITION, CROSSLINKED RUBBER PRODUCT AND MOLDED ARTICLE THEREOF, AND METHOD FOR PRODUCING DIARYLAMINE COMPOUND | ZEON CORP (JP) | 2016-12-14 | — | — | EP | disclosed |
| US-8883888-B2 | Diarylamine compounds, aging inhibitor, polymer composition, crosslinked rubber product and molded article of the crosslinked product, and method of producing diarylamine compound | ZEON CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2450348-A1 | NOVEL DIARYLAMINE COMPOUND, AND ANTI-AGING AGENT, POLYMER COMPOSITION, CROSSLINKED RUBBER PRODUCT AND MOLDED ARTICLE THEREOF, AND METHOD FOR PRODUCING DIARYLAMINE COMPOUND | Zeon Corporation (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101196-A1 | NOVEL DIARYLAMINE COMPOUNDS, AGING INHIBITOR, POLYMER COMPOSITION, CROSSLINKED RUBBER PRODUCT AND MOLDED ARTICLE OF THE CROSSLINKED PRODUCT, AND METHOD OF PRODUCING DIARYLAMINE COMPOUND | ZEON CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101196-A1 | NOVEL DIARYLAMINE COMPOUNDS, AGING INHIBITOR, POLYMER COMPOSITION, CROSSLINKED RUBBER PRODUCT AND MOLDED ARTICLE OF THE CROSSLINKED PRODUCT, AND METHOD OF PRODUCING DIARYLAMINE COMPOUND | CDKN1A, DDAH1, CCNI | POLB 1122/4885ALDH1A1 849/4885HPGD 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.